Q3 2019 Nektar Therapeutics Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Third Quarter 2019 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.
Thank you, Crystal. Good afternoon, everyone, and thank you for joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; and Dr. Jonathan Zalevsky, our Head of R&D.
On today's call, we expect to make forward-looking statements regarding our business, including clinical trial results, timing and plans for future clinical trials; timing and plans for future clinical data presentations at medical meetings; the therapeutic potential of our drug candidates; outcomes and plans for health authority regulatory actions and decisions; financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
